Regenera Pharma Ltd.
- Country
- 🇮🇱Israel
- Ownership
- Private
- Established
- 2009-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Efficacy & Safety of RPh201 Treatment in Patients With Previous Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
- Conditions
- Nonarteritic Anterior Ischemic Optic Neuropathy
- Interventions
- Drug: RPh201 Cohort AOther: Placebo Cohort ADrug: RPh201 Cohort BOther: Placebo Cohort B
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2020-10-12
- Lead Sponsor
- Regenera Pharma Ltd
- Target Recruit Count
- 165
- Registration Number
- NCT03547206
- Locations
- 🇺🇸
Byers Eye Institute at Stanford University, Palo Alto, California, United States
🇺🇸UCLA Doheny Eye Center, Pasadena, California, United States
🇺🇸The Eye Care Group, Waterbury, Connecticut, United States
A Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease
- Conditions
- Mild to Moderate Dementia Due to Alzheimer's DiseaseWith or Without Coexisting Cerebrovascular Disease
- Interventions
- Other: Placebo
- First Posted Date
- 2018-03-12
- Last Posted Date
- 2020-04-30
- Lead Sponsor
- Regenera Pharma Ltd
- Target Recruit Count
- 83
- Registration Number
- NCT03462121
- Locations
- 🇨🇦
Kawartha Centre - Redefining Healthy Aging, Peterborough, Ontario, Canada
🇨🇦Toronto Memory Program, Toronto, Ontario, Canada
🇨🇦Gerontion Research Inc., The Center for Memory & Aging, Toronto, Ontario, Canada
Safety and Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION).
- Conditions
- Non-arteritic Ischemic Optic NeuropathyOptic Nerve Injuries
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-01-24
- Last Posted Date
- 2020-03-19
- Lead Sponsor
- Regenera Pharma Ltd
- Target Recruit Count
- 22
- Registration Number
- NCT02045212
- Locations
- 🇮🇱
Ophthalmology Department, Western Galilee-Nahariya Medical Center, Nahariya, Israel
A Randomized SAD and MAD Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease
- Conditions
- Moderate to Severe Alzheimer PatientsHealthy Volunteers
- Interventions
- Drug: PlaceboDrug: RPh201, botanical drug product
- First Posted Date
- 2012-01-20
- Last Posted Date
- 2020-03-23
- Lead Sponsor
- Regenera Pharma Ltd
- Target Recruit Count
- 39
- Registration Number
- NCT01513967
- Locations
- 🇨🇦
Toronto Memory Program, Toronto, Ontario, Canada
🇨🇦Kendle Early Stage - Toronto, Toronto, Ontario, Canada
Trial To Evaluate RPh201 In Treatment Of Partial Thickness Burn
- Conditions
- Second Degree Burn Less Than 5%TBSAPartial Thickness Burn
- Interventions
- Drug: RPh201, botanical drug product
- First Posted Date
- 2011-10-20
- Last Posted Date
- 2016-12-06
- Lead Sponsor
- Regenera Pharma Ltd
- Registration Number
- NCT01455480
- Locations
- 🇮🇱
Clinic of the The Burn Unit, The Department of Plastic & Reconstructive Surgery and Medical Research Infrastructure Development and Health Services Fund by Chaim Sheba Medical Center, Tel Hashomer, Israel
- Prev
- 1
- 2
- Next